FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.14
−1.43%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.24
From 52W high−41.44%
Volume501994.00
Market cap$245.86M
P/E (TTM)—
P/S (TTM)6.7x
Div yield—
Key dataSep 18, 2026
Open
$4.24
From 52W high
−41.44%
Volume
501994.00
Market cap
$245.86M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
26.5
MomentumView details →
1D Return
−1.43%
YTD Return
−23.33%
SummaryUpdated Jun 1, 2026
Foghorn Therapeutics Inc. (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in October 2020 and focuses on discovering and developing innovative cancer treatments by targeting the chromatin regulatory system, a fundamental cellular mechanism that controls gene expression. Foghorn has built its drug discovery efforts around a proprietary platform called Gene Traffic Control, which identifies vulnerabilities in cancer cells that can be exploited with targeted therapies.
Similar companies
Latest newsMore news →